EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis

Zedong Sun, Minmin Zhou, Can Wang, Mingrui Liu, Ningdan Song, Simian He, Feifan Ji, Jiayu Chen, Lin Xu, Xiufen Zheng, Binhui Ren iD

Cellular Oncology · 2026

DOI: 10.1007/s13402-026-01263-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Zedong Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Researc…. Hauptthemen laut MEDLINE: Ferroptosis, Cisplatin, Homeodomain Proteins, Adenocarcinoma of Lung. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Youth Cultivation Funding of the First Affiliated Hospital of Hainan Medical University, Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Innovation Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisCisplatinHomeodomain ProteinsAdenocarcinoma of LungLung NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseTranscription FactorsHumansAnimalsCell Line, TumorGene Expression Regulation, NeoplasticCell ProliferationMice, NudeMiceDrug Resistance, NeoplasmFemaleXenograft Model Antitumor AssaysUp-Regulation

Stichwörter der Autor:innen

CisplatinDLX6FerroptosisGPX4Lung adenocarcinoma

Substanzen

CisplatinHomeodomain ProteinsPhospholipid Hydroperoxide Glutathione PeroxidaseDLX6 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
  • Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Cancer Institute of Jiangsu Province, Nanjing, People's Republic of China.
  • The Fourth Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
  • China Pharmaceutical University, Nanjing, People's Republic of China.
  • Department of Thoracic Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Researc…
  • Department of Pharmacy and Engineering Research Center of Tropical Medicine Innovation and Transformation, Key Laboratory of Emergency and Trauma of Ministry of Education, The First Affiliated Hospital, Hainan Medical U…

ORCID-Profile: Binhui Ren

Förderung

  • National Natural Science Foundation of China
  • Youth Cultivation Funding of the First Affiliated Hospital of Hainan Medical University
  • Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Innovation Center

Zitieren

APA

Sun, Z., Zhou, M., Wang, C., Liu, M., Song, N., He, S., Ji, F., Chen, J., Xu, L., Zheng, X., & Ren, B. (2026). Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis. Cellular Oncology. https://doi.org/10.1007/s13402-026-01263-w

Vancouver

Sun Z, Zhou M, Wang C, Liu M, Song N, He S, et al. Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis. Cellular Oncology. 2026. doi:10.1007/s13402-026-01263-w

BibTeX
@article{Sun2026,
  author = {Sun, Zedong and Zhou, Minmin and Wang, Can and Liu, Mingrui and Song, Ningdan and He, Simian and Ji, Feifan and Chen, Jiayu and Xu, Lin and Zheng, Xiufen and Ren, Binhui},
  title = {Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01263-w}
}
Kostenlos starten →